{
  "paper_id": "PMC10031335",
  "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10031335/",
  "figures": {
    "figure_1": {
      "figure_number": "Figure 1",
      "title": "Figure 1.",
      "caption": "Flow diagram of the study selection process. BVS, biblioteva virtual de saude (virtual healthcare library); QOL, quality of life; HRQOL, health-related quality of life.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e6c/10031335/6ab368769053/gr1.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e6c/10031335/6ab368769053/gr1.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e6c/10031335/6ab368769053/gr1.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e6c/10031335/6ab368769053/gr1.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "fig1",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e6c/10031335/6ab368769053/gr1.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC10031335/images/figure_1.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e6c/10031335/6ab368769053/gr1.jpg"
    },
    "figure_2": {
      "figure_number": "Figure 2",
      "title": "Figure 2.",
      "caption": "Meta-analysis of total HRQOL scores according to QOL assessment instruments. Higher scores indicate better HRQOL (range, 0 to 100). To match the amplitude and effect direction of most instruments, EQ-5D-3L scores are presented as 100 times the original figures and Haemo-QoL scores are presented as 100 minus the original scores because, originally, higher scores indicated worse QOL in the Haemo-QoL questionnaire. All other scores are presented on the original scale of each specific instrument. TE, treatment effect; seTE, standard error for treatment effect; HRQoL, health-related quality of life; CI, confidence interval.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e6c/10031335/20cecf6bc3d9/gr2.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e6c/10031335/20cecf6bc3d9/gr2.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e6c/10031335/20cecf6bc3d9/gr2.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e6c/10031335/20cecf6bc3d9/gr2.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "fig2",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e6c/10031335/20cecf6bc3d9/gr2.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC10031335/images/figure_2.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e6c/10031335/20cecf6bc3d9/gr2.jpg"
    }
  },
  "claims": [
    {
      "sentence": "Figure 1 shows the flow diagram of the study selection process.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Figure 2 shows the total and subgroup meta-analyses for the total HRQoL scores by the type of instrument.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A comparative meta-analysis of the 2 studies that provided sufficient information to directly compare the mean total HRQoL scores, as measured with EQ-5D-3L and PedsQL, between patients with and without FVIII inhibitors indicated a statistically significant increase in the SMD of HRQoL scores favoring patients without FVIII inhibitors (Supplementary Fig. 3; SMD = 0.57; 95% CI, 0.18-0.97; I2 = 0.0%) [32,40].",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The meta-regression analysis also demonstrated that 3 of the 6 studies with the highest HRQoL scores (mean total Haemo-QoL score of <30) were treated with hemostatic agents such as turoctocog alfa (in 2 studies) and emicizumab (in 1 study) (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Publication bias assessment revealed a highly heterogeneous yet fairly balanced distribution of data points in the funnel plot for the 14 studies that used the Haemo-QoL questionnaire (Supplementary Fig. 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Figure 1 shows the flow diagram of the study selection process.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Figure 2 shows the total and subgroup meta-analyses for the total HRQoL scores by the type of instrument.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A comparative meta-analysis of the 2 studies that provided sufficient information to directly compare the mean total HRQoL scores, as measured with EQ-5D-3L and PedsQL, between patients with and without FVIII inhibitors indicated a statistically significant increase in the SMD of HRQoL scores favoring patients without FVIII inhibitors (Supplementary Fig. 3; SMD = 0.57; 95% CI, 0.18-0.97; I2 = 0.0%) [32,40].",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The meta-regression analysis also demonstrated that 3 of the 6 studies with the highest HRQoL scores (mean total Haemo-QoL score of <30) were treated with hemostatic agents such as turoctocog alfa (in 2 studies) and emicizumab (in 1 study) (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Publication bias assessment revealed a highly heterogeneous yet fairly balanced distribution of data points in the funnel plot for the 14 studies that used the Haemo-QoL questionnaire (Supplementary Fig. 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Figure 1 shows the flow diagram of the study selection process.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Figure 2 shows the total and subgroup meta-analyses for the total HRQoL scores by the type of instrument.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A comparative meta-analysis of the 2 studies that provided sufficient information to directly compare the mean total HRQoL scores, as measured with EQ-5D-3L and PedsQL, between patients with and without FVIII inhibitors indicated a statistically significant increase in the SMD of HRQoL scores favoring patients without FVIII inhibitors (Supplementary Fig. 3; SMD = 0.57; 95% CI, 0.18-0.97; I2 = 0.0%) [32,40].",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The meta-regression analysis also demonstrated that 3 of the 6 studies with the highest HRQoL scores (mean total Haemo-QoL score of <30) were treated with hemostatic agents such as turoctocog alfa (in 2 studies) and emicizumab (in 1 study) (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Publication bias assessment revealed a highly heterogeneous yet fairly balanced distribution of data points in the funnel plot for the 14 studies that used the Haemo-QoL questionnaire (Supplementary Fig. 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Figure 1 shows the flow diagram of the study selection process.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Figure 2 shows the total and subgroup meta-analyses for the total HRQoL scores by the type of instrument.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A comparative meta-analysis of the 2 studies that provided sufficient information to directly compare the mean total HRQoL scores, as measured with EQ-5D-3L and PedsQL, between patients with and without FVIII inhibitors indicated a statistically significant increase in the SMD of HRQoL scores favoring patients without FVIII inhibitors (Supplementary Fig. 3; SMD = 0.57; 95% CI, 0.18-0.97; I2 = 0.0%) [32,40].",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The meta-regression analysis also demonstrated that 3 of the 6 studies with the highest HRQoL scores (mean total Haemo-QoL score of <30) were treated with hemostatic agents such as turoctocog alfa (in 2 studies) and emicizumab (in 1 study) (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Publication bias assessment revealed a highly heterogeneous yet fairly balanced distribution of data points in the funnel plot for the 14 studies that used the Haemo-QoL questionnaire (Supplementary Fig. 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Figure 1 shows the flow diagram of the study selection process.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Figure 2 shows the total and subgroup meta-analyses for the total HRQoL scores by the type of instrument.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A comparative meta-analysis of the 2 studies that provided sufficient information to directly compare the mean total HRQoL scores, as measured with EQ-5D-3L and PedsQL, between patients with and without FVIII inhibitors indicated a statistically significant increase in the SMD of HRQoL scores favoring patients without FVIII inhibitors (Supplementary Fig. 3; SMD = 0.57; 95% CI, 0.18-0.97; I2 = 0.0%) [32,40].",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The meta-regression analysis also demonstrated that 3 of the 6 studies with the highest HRQoL scores (mean total Haemo-QoL score of <30) were treated with hemostatic agents such as turoctocog alfa (in 2 studies) and emicizumab (in 1 study) (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Publication bias assessment revealed a highly heterogeneous yet fairly balanced distribution of data points in the funnel plot for the 14 studies that used the Haemo-QoL questionnaire (Supplementary Fig. 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Figure 1 shows the flow diagram of the study selection process.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Figure 2 shows the total and subgroup meta-analyses for the total HRQoL scores by the type of instrument.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A comparative meta-analysis of the 2 studies that provided sufficient information to directly compare the mean total HRQoL scores, as measured with EQ-5D-3L and PedsQL, between patients with and without FVIII inhibitors indicated a statistically significant increase in the SMD of HRQoL scores favoring patients without FVIII inhibitors (Supplementary Fig. 3; SMD = 0.57; 95% CI, 0.18-0.97; I2 = 0.0%) [32,40].",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The meta-regression analysis also demonstrated that 3 of the 6 studies with the highest HRQoL scores (mean total Haemo-QoL score of <30) were treated with hemostatic agents such as turoctocog alfa (in 2 studies) and emicizumab (in 1 study) (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Publication bias assessment revealed a highly heterogeneous yet fairly balanced distribution of data points in the funnel plot for the 14 studies that used the Haemo-QoL questionnaire (Supplementary Fig. 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Figure 1 shows the flow diagram of the study selection process.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Figure 2 shows the total and subgroup meta-analyses for the total HRQoL scores by the type of instrument.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A comparative meta-analysis of the 2 studies that provided sufficient information to directly compare the mean total HRQoL scores, as measured with EQ-5D-3L and PedsQL, between patients with and without FVIII inhibitors indicated a statistically significant increase in the SMD of HRQoL scores favoring patients without FVIII inhibitors (Supplementary Fig. 3; SMD = 0.57; 95% CI, 0.18-0.97; I2 = 0.0%) [32,40].",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The meta-regression analysis also demonstrated that 3 of the 6 studies with the highest HRQoL scores (mean total Haemo-QoL score of <30) were treated with hemostatic agents such as turoctocog alfa (in 2 studies) and emicizumab (in 1 study) (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Publication bias assessment revealed a highly heterogeneous yet fairly balanced distribution of data points in the funnel plot for the 14 studies that used the Haemo-QoL questionnaire (Supplementary Fig. 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Figure 1 shows the flow diagram of the study selection process.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Figure 2 shows the total and subgroup meta-analyses for the total HRQoL scores by the type of instrument.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A comparative meta-analysis of the 2 studies that provided sufficient information to directly compare the mean total HRQoL scores, as measured with EQ-5D-3L and PedsQL, between patients with and without FVIII inhibitors indicated a statistically significant increase in the SMD of HRQoL scores favoring patients without FVIII inhibitors (Supplementary Fig. 3; SMD = 0.57; 95% CI, 0.18-0.97; I2 = 0.0%) [32,40].",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The meta-regression analysis also demonstrated that 3 of the 6 studies with the highest HRQoL scores (mean total Haemo-QoL score of <30) were treated with hemostatic agents such as turoctocog alfa (in 2 studies) and emicizumab (in 1 study) (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Publication bias assessment revealed a highly heterogeneous yet fairly balanced distribution of data points in the funnel plot for the 14 studies that used the Haemo-QoL questionnaire (Supplementary Fig. 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Figure 1 shows the flow diagram of the study selection process.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Figure 2 shows the total and subgroup meta-analyses for the total HRQoL scores by the type of instrument.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A comparative meta-analysis of the 2 studies that provided sufficient information to directly compare the mean total HRQoL scores, as measured with EQ-5D-3L and PedsQL, between patients with and without FVIII inhibitors indicated a statistically significant increase in the SMD of HRQoL scores favoring patients without FVIII inhibitors (Supplementary Fig. 3; SMD = 0.57; 95% CI, 0.18-0.97; I2 = 0.0%) [32,40].",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The meta-regression analysis also demonstrated that 3 of the 6 studies with the highest HRQoL scores (mean total Haemo-QoL score of <30) were treated with hemostatic agents such as turoctocog alfa (in 2 studies) and emicizumab (in 1 study) (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Publication bias assessment revealed a highly heterogeneous yet fairly balanced distribution of data points in the funnel plot for the 14 studies that used the Haemo-QoL questionnaire (Supplementary Fig. 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Figure 1 shows the flow diagram of the study selection process.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Figure 2 shows the total and subgroup meta-analyses for the total HRQoL scores by the type of instrument.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A comparative meta-analysis of the 2 studies that provided sufficient information to directly compare the mean total HRQoL scores, as measured with EQ-5D-3L and PedsQL, between patients with and without FVIII inhibitors indicated a statistically significant increase in the SMD of HRQoL scores favoring patients without FVIII inhibitors (Supplementary Fig. 3; SMD = 0.57; 95% CI, 0.18-0.97; I2 = 0.0%) [32,40].",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The meta-regression analysis also demonstrated that 3 of the 6 studies with the highest HRQoL scores (mean total Haemo-QoL score of <30) were treated with hemostatic agents such as turoctocog alfa (in 2 studies) and emicizumab (in 1 study) (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Publication bias assessment revealed a highly heterogeneous yet fairly balanced distribution of data points in the funnel plot for the 14 studies that used the Haemo-QoL questionnaire (Supplementary Fig. 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    }
  ],
  "extraction_stats": {
    "figures_count": 2,
    "claims_count": 50,
    "images_downloaded": 2,
    "tables_filtered": 43
  }
}